CNSI Cambridge Neuroscience Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CNSI Cambridge Neuroscience

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: NeuroInvestment who wrote (168)	5/23/1997 12:34:00 AM
From: Miljenko Zuanic	of 675

NI, My point was that CNSI and NTII are not "direct" competitors even they have (or will have) drugs in clinicals for some indication. Memantine is "re-discovered" molecule (after anti-Parkinsonian's), but I have reservation that it will be effective in acute ischaemic conditions. Help me to understand: NMDA Calcium channel agonist (glutamate) has two negative charge site(di-acid) which "care" calcium ion (two positive charge) through neuron membrane. How can Memantine (mono-amin) compete with elevated concentration of the Ca ions (pKb for Calcium ion is greater than pKb for Memantine) and effectively inhibit influx of Ca ions in to neurons? On the other hand, guanidine and hydrazine derivatives (two amino groups) can bind to Glutamate's positive charge competitively to Ca ions. Thanks in advance. mz

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next